ANN ARBOR, Mich., (April 28, 2014) – NanoBio Corporation today announced that the company will present new data at the National Foundation for Infectious Diseases’ 17th Annual Conference on Vaccine Research (NFID ACVR ), demonstrating the benefits of its nanoemulsion (NE) adjuvant in the development of an intranasal herpes simplex virus-2 (HSV-2) vaccine. Read more
ANN ARBOR, Mich., (October 29, 2013) – NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. Read more
ANN ARBOR, Mich., (September 11, 2013) – NanoBio Corporation today announced that the company will present new data at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting showing the safety and efficacy of a nanoemulsion (NE) adjuvanted intramuscular vaccine for the prevention of respiratory syncytial virus (RSV). RSV plagues nearly all children by the age of three and can be life-threatening for premature babies, children with other health conditions, and the elderly. Currently, a vaccine for the prevention of RSV is not commercially available. Read more
ANN ARBOR, Mich., (April 23, 2013) – NanoBio Corporation today announced that the company will present new data demonstrating positive pre-clinical results for its intramuscular (IM) respiratory syncytial virus (RSV) vaccine at the National Foundation for Infectious Diseases (NFID) 16th Annual Conference on Vaccine Research (ACVR). The new research shows that NanoBio’s intramuscular nanoemulsion-adjuvanted respiratory syncytial virus (NE-RSV) vaccine, derived from the company’s novel NanoStat® Technology, was safe and highly effective in protecting cotton rats against RSV without causing enhanced disease. NFID 2013 will take place April 22-24, 2013 in Baltimore, MD. Read more
ANN ARBOR, Mich. (November 28, 2012) – NanoBio Corporation announced today the closing of an $11 million Series C financing, including full participation from its existing investor syndicate. Proceeds from the financing will be used to advance the company’s development programs for herpes labialis (cold sores), cystic fibrosis and nanoemulsion-based vaccines for respiratory syncytial virus (RSV) and genital herpes (HSV2). Read more
ANN ARBOR, Mich. and SAN DIEGO (October 15, 2012) – NanoBio Corporation announced today that results from its nanoemulsion adjuvanted RSV vaccine will be presented at IDWeek 2012™ taking place from Oct. 17-21 in San Diego. Read more
ANN ARBOR, Mich. (October 9, 2012) – NanoBio® Corporation today announced the promotion of David Peralta to chief executive officer. Mr. Peralta, who previously served as the company’s chief operating and financial officer, replaces James R. Baker, Jr. M.D., who recently joined Merck & Co. as the senior vice president, head global vaccine franchise. As the scientific founder and inventor of NanoBio’s patented NanoStat™ technology platform, Dr. Baker will continue to serve on NanoBio’s Board of Directors. Read more
ANN ARBOR, Mich. and SANTA FE, N.M. (September 24, 2012) – NanoBio® Corporation announced today it will present data from three preclinical studies at the 8th Annual International Respiratory Syncytial Virus (RSV) Symposium taking place from Sept. 27-30 in Santa Fe, N.M. Read more
ANN ARBOR, Mich. (September 10, 2012) – NanoBio Corporation announced today it will present data from two separate preclinical studies at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting currently underway in San Francisco. Read more